Atricure (ATRC) Stock Forecast & Price Target

Compare

377 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

ATRC Analyst Ratings

Strong Buy

5 Buy

0 Hold

0 Sell

Based on 5 analysts giving stock ratings to

Atricure

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

ATRC Stock 12 Month Forecast

Average Price Target

$52.60

▲(59.88% Upside)

Based on 5 Wall Street analysts offering 12 month price targets for Atricure in the last 3 months. The average price target is $52.60 with a high forecast of $64.00 and a low forecast of $45.00. The average price target represents a 59.88% change from the last price of $32.90.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"28":"$28","65":"$65","37.25":"$37.3","46.5":"$46.5","55.75":"$55.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":64,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$64.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":52.6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$52.60</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":45,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$45.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[28,37.25,46.5,55.75,65],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Feb<br/>2025","6":"May<br/>2025","9":"Aug<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,34.55,36.815384615384616,39.08076923076923,41.34615384615385,43.61153846153846,45.87692307692308,48.142307692307696,50.40769230769231,52.67307692307692,54.93846153846154,57.20384615384616,59.46923076923077,61.73461538461539,{"y":64,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,34.55,35.93846153846154,37.32692307692307,38.715384615384615,40.10384615384615,41.49230769230769,42.88076923076923,44.269230769230774,45.65769230769231,47.04615384615384,48.434615384615384,49.823076923076925,51.21153846153847,{"y":52.6,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,34.55,35.35384615384615,36.15769230769231,36.96153846153846,37.76538461538461,38.56923076923077,39.37307692307692,40.176923076923075,40.980769230769226,41.784615384615385,42.58846153846154,43.392307692307696,44.19615384615385,{"y":45,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":33.51,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":37.06,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.56,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":39.87,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":38.74,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.36,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.29,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.2,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.41,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":36.29,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.23,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.55,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$64.00

Average Price Target$52.60

Lowest Price Target$45.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Rick Wise

Stifel Nicolaus

$48→$50

Buy

51.98%

Upside

Reiterated

10/30/25

Stifel Nicolaus Keeps Their Buy Rating on Atricure (ATRC)New Products Power Another Solid, Mid-Teens Growth Quarter as Innovation Pipeline Progress Continues

Michael Matson

Needham

$45

Buy

36.78%

Upside

Reiterated

10/30/25

Atricure's Strong Q3 Performance and Growth Potential Justify Buy RatingWe view ATRC's guidance and 2026 consensus estimates as conservative and see potential for its new product launches to drive additional revenue and EBITDA upside, and we reiterate our Buy rating.

Matthew O'Brien

Piper Sandler

$50

Buy

51.98%

Upside

Reiterated

10/30/25

Analysts Offer Insights on Healthcare Companies: Atricure (NASDAQ: ATRC), Tectonic Therapeutic (NASDAQ: TECX) and Akebia Therapeutics (NASDAQ: AKBA)

Marie Thibault

BTIG

$54

Buy

64.13%

Upside

Reiterated

10/30/25

BTIG Sticks to Its Buy Rating for Atricure (ATRC)We reiterate our Buy rating and $54 PT.

William Plovanic

Canaccord Genuity

$53→$64

Buy

94.53%

Upside

Reiterated

10/29/25

Atricure (ATRC) Gets a Buy from Canaccord Genuity

Daniel Stauder

Citizens JMP

$60

Buy

82.37%

Upside

Reiterated

07/30/25

Citizens JMP Sticks to Its Buy Rating for Atricure (ATRC)We reiterate our Market Outperform rating and $60 price target on AtriCure following the companys full 2Q25 results, which reflected top- and bottom-line beats to Street expectations as well as corresponding guidance raises.

Danielle Antalffy

UBS

$58

Buy

76.29%

Upside

Reiterated

07/30/25

UBS Sticks to Their Buy Rating for Atricure (ATRC)

Lilia-Celine (Lily) Lozada

J.P. Morgan

$46→$42

Buy

27.66%

Upside

Reiterated

07/30/25

J.P. Morgan Remains a Buy on Atricure (ATRC)

Suraj Kalia

Oppenheimer

$45→$40

Buy

21.58%

Upside

Reiterated

04/30/25

Analysts' Opinions Are Mixed on These Healthcare Stocks: The Ensign Group (NASDAQ: ENSG), Verona Pharma (NASDAQ: VRNA) and Atricure (NASDAQ: ATRC)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Rick Wise

Stifel Nicolaus

$48→$50

Buy

51.98%

Upside

Reiterated

10/30/25

Stifel Nicolaus Keeps Their Buy Rating on Atricure (ATRC)New Products Power Another Solid, Mid-Teens Growth Quarter as Innovation Pipeline Progress Continues

Michael Matson

Needham

$45

Buy

36.78%

Upside

Reiterated

10/30/25

Matthew O'Brien

Piper Sandler

$50

Buy

51.98%

Upside

Reiterated

10/30/25

Analysts Offer Insights on Healthcare Companies: Atricure (NASDAQ: ATRC), Tectonic Therapeutic (NASDAQ: TECX) and Akebia Therapeutics (NASDAQ: AKBA)

Marie Thibault

BTIG

$54

Buy

64.13%

Upside

Reiterated

10/30/25

BTIG Sticks to Its Buy Rating for Atricure (ATRC)We reiterate our Buy rating and $54 PT.

William Plovanic

Canaccord Genuity

$53→$64

Buy

94.53%

Upside

Reiterated

10/29/25

Atricure (ATRC) Gets a Buy from Canaccord Genuity

Daniel Stauder

Citizens JMP

$60

Buy

82.37%

Upside

Reiterated

07/30/25

Danielle Antalffy

UBS

$58

Buy

76.29%

Upside

Reiterated

07/30/25

UBS Sticks to Their Buy Rating for Atricure (ATRC)

Lilia-Celine (Lily) Lozada

J.P. Morgan

$46→$42

Buy

27.66%

Upside

Reiterated

07/30/25

J.P. Morgan Remains a Buy on Atricure (ATRC)

Suraj Kalia

Oppenheimer

$45→$40

Buy

21.58%

Upside

Reiterated

04/30/25

Analysts' Opinions Are Mixed on These Healthcare Stocks: The Ensign Group (NASDAQ: ENSG), Verona Pharma (NASDAQ: VRNA) and Atricure (NASDAQ: ATRC)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Atricure

1 Month

xxx

Success Rate

15/23 ratings generated profit

Average Return

+4.21%

reiterated a xxx

rating 8 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 65.22% of your transactions generating a profit, with an average return of +4.21% per trade.

3 Months

xxx

Success Rate

15/23 ratings generated profit

Average Return

+11.18%

reiterated a xxx

rating 8 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 65.22% of your transactions generating a profit, with an average return of +11.18% per trade.

1 Year

Suraj KaliaOppenheimer

Success Rate

20/23 ratings generated profit

Average Return

+41.26%

reiterated a buy rating 8 months ago

Copying Suraj Kalia's trades and holding each position for 1 Year would result in 86.96% of your transactions generating a profit, with an average return of +41.26% per trade.

2 Years

xxx

Success Rate

23/23 ratings generated profit

Average Return

+60.60%

reiterated a xxx

rating 8 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +60.60% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ATRC Analyst Recommendation Trends

Rating

Jul 25

Aug 25

Sep 25

Oct 25

Nov 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, ATRC has received 6 Buy Ratings, 5 Hold Ratings, and 0 Sell Ratings. ATRC average Analyst price target in the past 3 months is 52.60.

Each month's total comprises the sum of three months' worth of ratings.

ATRC Financial Forecast

ATRC Earnings Forecast

Next quarter’s earnings estimate for ATRC is -$0.10 with a range of -$0.21 to $0.04. The previous quarter’s EPS was -$0.01. ATRC beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year ATRC has Performed in-line its overall industry.

ATRC Sales Forecast

Next quarter’s sales forecast for ATRC is $139.29M with a range of $139.00M to $139.62M. The previous quarter’s sales results were $134.27M. ATRC beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year ATRC has Performed in-line its overall industry.

ATRC Stock Forecast FAQ

What is ATRC’s average 12-month price target, according to analysts?

Based on analyst ratings, Atricure, Inc.’s 12-month average price target is 52.60.

What is ATRC’s upside potential, based on the analysts’ average price target?

Atricure, Inc. has 59.88% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is ATRC a Buy, Sell or Hold?

Atricure, Inc. has a consensus rating of Strong Buy which is based on 5 buy ratings, 0 hold ratings and 0 sell ratings.

What is Atricure, Inc.’s price target?

The average price target for Atricure, Inc. is 52.60. This is based on 5 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $64.00 ,the lowest forecast is $45.00. The average price target represents 59.88% Increase from the current price of $32.9.

What do analysts say about Atricure, Inc.?

Atricure, Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 5 Wall Streets Analysts.

How can I buy shares of ATRC?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Atricure (ATRC) Stock Forecast & Price Target

ATRC Analyst Ratings

ATRC Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Atricure

ATRC Analyst Recommendation Trends

ATRC Financial Forecast

ATRC Earnings Forecast

ATRC Sales Forecast

ATRC Stock Forecast FAQ

Detailed List of Analyst Forecasts